Patricia Parris, AstraZeneca - Qepler Summits And Conferences

Patricia Parris

Project Toxicologist (RIA Safety)
Royston, United Kingdom
AstraZeneca is a global, science-led biopharmaceutical business and our innovative medicines are used by millions of patients worldwide.

Trish is a Project Toxicologist in Drug Safety & Metabolism within AstraZeneca and has a background in Genetic Toxicology.

She joined AstraZeneca in 2015 and in addition to managing the non-clinical safety strategy for respiratory and inflammatory disease pharmaceuticals she has a global role providing guidance on all aspects of drug impurity issues.

In recent years, Trish has worked with the ICH M7 sub-group to develop the Addendum table co-authoring the hydrogen peroxide monograph; and the vinyl acetate monograph in the subsequent publication Bercu et al., (2018).

Trish is also the co-chair of the Extractables and Leachables Safety Information Exchange (ELSIE) PDE Sub-team.

Related Sessions:

Genotoxic Impurities in
Pharmaceuticals Summit 2019

GTI strategies & new methodologies: analysis, in silico & regulations. Challenges & opportunities.
  • 11 Apr 2019
  • Berlin, DE
  • Pharma
Day 1: Thursday, 11 April 2019
CASE STUDY: Challenges calculating compound-specific exposure limits.
  • ICH M7 guideline status
  • Key principles of the guideline
  • Key publications and their impact
  • Valsartan and beyond
View Details